Cipla's InvaGen US facility gets USFDA inspection closure report

Regulatory & Legal View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.0%Reaction day

₹1460.50

prior close

₹1469.60

announcement price

After-mkt

timing

Nifty 100market-0.6%+0.6% vs market

Pharmaceuticals peers, median of 165sector+0.0%-0.0% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty 100 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.7

15m

-0.8

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.0-0.6+0.6+0.0-0.0

Next day

-0.1-0.5+0.4+0.0-0.1

+1.1-0.5+1.6+0.2+1.0

+0.7-0.6+1.3+0.4+0.2

+0.5-0.6+1.1+0.6-0.1

+0.2-1.0+1.2+0.9-0.7

-0.2-1.2+1.0+0.6-0.8

15d

-2.6-1.5-1.2+0.5-3.2

-5.2-3.3-1.9+1.1-6.3

-8.6-8.6+0.1+2.1-10.7

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cipla's wholly-owned subsidiary InvaGen Pharmaceuticals has received the Establishment Inspection Report (EIR) from the USFDA for its Hauppauge, Long Island, New York manufacturing facility. The EIR indicates closure of the Pre-Approval Inspection conducted earlier in February 2026, suggesting the facility met USFDA requirements without adverse action.

Likely market impact

Positive for shareholders: USFDA inspection closure removes regulatory overhang and supports continued US supplies from the facility.